This data report presents the complete Cell Surface Multi-Omics analysis of KRAS-knockdown and wild-type HCT-116 cells, including cell surface proteomics, membrane lipidomics, differential expression analysis and integrated protein–lipid interpretation from matched membrane fractions.
KRAS Knockdown Remodels Surface Proteins and Lipids Cell Surface Multi-Omics combines cell surface proteomics and membrane lipidomics from matched membrane fractions to characterize the protein and lipid architecture of the cell surface. In KRAS-knockdown HCT-116 cells, integrated profiling revealed coordinated remodeling of surface receptors, transport proteins, and membrane lipid classes associated with membrane organization and […]
Why Cell Therapy Target Selection Is So Difficult Antibody-drug conjugates (ADCs) and CAR-T therapies have reshaped modern oncology, but their success still depends on one deceptively simple question: are we targeting the right protein? In practice, answering this is anything but simple. A clinically viable target must be present on tumor cells at sufficient levels, […]
Drug development is expensive, slow, and highly unpredictable. Despite major advances in genomics and precision medicine, nearly 90% of drug candidates still fail (Doi: 10.1016/j.apsb.2022.02.002) during clinical development, often because the selected target was not sufficiently validated early on. One of the biggest blind spots in drug discovery is the cell surface proteome: the collection of […]
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes with agents like trastuzumab emtansine (Kadcyla) and brentuximab vedotin (Adcetris), ADC development remains challenged by complex optimization requirements spanning target selection, payload […]